NCT03472235

Microneedle and Trichloroaceticacid in Treatment of Melasma

Status unknown NA Last updated 21 March 2018

What this trial tests

NA trial testing Microneedle in Melasma in 40 participants. Status unknown.

Timeline

5 April 2018

Primary endpoint
5 April 2019

5 April 2020

Quick facts

Lead sponsor	Assiut University
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	40
Start date	5 April 2018
Primary completion	5 April 2019
Estimated completion	5 April 2020

Drugs / interventions tested

• Microneedle

Conditions studied

• Melasma — all drugs for Melasma →

Sponsor

Assiut University

Who can join

Adults 18 to 50, any sex, with Melasma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Melasma is an acquired disorder of hyperpigmentation characterised by blotchy, light-to-dark brown macules distributed symmetrically on the sun-exposed parts of the body.

Although many factors have been proposed to have a role in pathogenesis, the exact ethology is yet to be understood. The most commonly identifiable risk factors include ultraviolet radiation, genetic predisposition, pregnancy, oral contraceptives, thyroid disease and drugs like antiepileptic. The excessive pigmentation has been attributed to both melanocytosis (increased number of melanocytes) as well as melano genesis (excess production of melanin) as confirmed in a histopathological study on Asian patients.\] Furthermore, a vascular component has also been proposed to play a role in the pathogenesis of melisma. Kim et al. have found that lesion melasma skin had greater expression of the vascular endothelial growth factor in keratinocytes compared to nearby nonlesional skin.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

1. Advanced nanocarrier- and microneedle-based transdermal drug delivery strategies for skin diseases treatment.
   Qu F, Geng R, Liu Y, Zhu J. · · 2022 · cited 162× · PMID 35547773 · DOI 10.7150/thno.69999
2. Microneedles as a Promising Technology for Disease Monitoring and Drug Delivery: A Review.
   Hulimane Shivaswamy R, Binulal P, Benoy A, Lakshmiramanan K, et al · · 2025 · cited 15× · PMID 39802146 · DOI 10.1021/acsmaterialsau.4c00125